BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20406820)

  • 1. Potentiation of disease-associated cystic fibrosis transmembrane conductance regulator mutants by hydrolyzable ATP analogs.
    Miki H; Zhou Z; Li M; Hwang TC; Bompadre SG
    J Biol Chem; 2010 Jun; 285(26):19967-75. PubMed ID: 20406820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of G551D-CFTR (cystic fibrosis transmembrane conductance regulator) potentiation by a high affinity ATP analog.
    Bompadre SG; Li M; Hwang TC
    J Biol Chem; 2008 Feb; 283(9):5364-9. PubMed ID: 18167357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects.
    Bompadre SG; Sohma Y; Li M; Hwang TC
    J Gen Physiol; 2007 Apr; 129(4):285-98. PubMed ID: 17353351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The most common cystic fibrosis-associated mutation destabilizes the dimeric state of the nucleotide-binding domains of CFTR.
    Jih KY; Li M; Hwang TC; Bompadre SG
    J Physiol; 2011 Jun; 589(Pt 11):2719-31. PubMed ID: 21486785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator.
    Yu YC; Sohma Y; Hwang TC
    J Physiol; 2016 Jun; 594(12):3227-44. PubMed ID: 26846474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin and genistein additively potentiate G551D-CFTR.
    Yu YC; Miki H; Nakamura Y; Hanyuda A; Matsuzaki Y; Abe Y; Yasui M; Tanaka K; Hwang TC; Bompadre SG; Sohma Y
    J Cyst Fibros; 2011 Jul; 10(4):243-52. PubMed ID: 21441077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The two ATP binding sites of cystic fibrosis transmembrane conductance regulator (CFTR) play distinct roles in gating kinetics and energetics.
    Zhou Z; Wang X; Liu HY; Zou X; Li M; Hwang TC
    J Gen Physiol; 2006 Oct; 128(4):413-22. PubMed ID: 16966475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel.
    Cai Z; Taddei A; Sheppard DN
    J Biol Chem; 2006 Jan; 281(4):1970-7. PubMed ID: 16311240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels.
    Wang F; Zeltwanger S; Hu S; Hwang TC
    J Physiol; 2000 May; 524 Pt 3(Pt 3):637-48. PubMed ID: 10790148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Converting nonhydrolyzable nucleotides to strong cystic fibrosis transmembrane conductance regulator (CFTR) agonists by gain of function (GOF) mutations.
    Okeyo G; Wang W; Wei S; Kirk KL
    J Biol Chem; 2013 Jun; 288(24):17122-33. PubMed ID: 23620589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanosensitivity of wild-type and G551D cystic fibrosis transmembrane conductance regulator (CFTR) controls regulatory volume decrease in simple epithelia.
    Xie C; Cao X; Chen X; Wang D; Zhang WK; Sun Y; Hu W; Zhou Z; Wang Y; Huang P
    FASEB J; 2016 Apr; 30(4):1579-89. PubMed ID: 26683699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.
    Lin WY; Sohma Y; Hwang TC
    Mol Pharmacol; 2016 Sep; 90(3):275-85. PubMed ID: 27413118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single amino acid substitution in CFTR converts ATP to an inhibitory ligand.
    Lin WY; Jih KY; Hwang TC
    J Gen Physiol; 2014 Oct; 144(4):311-20. PubMed ID: 25225552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle.
    Jih KY; Hwang TC
    Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4404-9. PubMed ID: 23440202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
    Yeh JT; Yu YC; Hwang TC
    J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis transmembrane conductance regulator: a chloride channel gated by ATP binding and hydrolysis.
    Bompadre SG; Hwang TC
    Sheng Li Xue Bao; 2007 Aug; 59(4):431-42. PubMed ID: 17700963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004.
    Dérand R; Bulteau-Pignoux L; Becq F
    J Membr Biol; 2003 Jul; 194(2):109-17. PubMed ID: 14502435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease.
    Pasyk S; Li C; Ramjeesingh M; Bear CE
    Biochem J; 2009 Feb; 418(1):185-90. PubMed ID: 18945216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of the degenerated interfacial ATP binding site improves the function of disease-related mutant cystic fibrosis transmembrane conductance regulator (CFTR) channels.
    Tsai MF; Jih KY; Shimizu H; Li M; Hwang TC
    J Biol Chem; 2010 Nov; 285(48):37663-71. PubMed ID: 20861014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revertant mutants modify, but do not rescue, the gating defect of the cystic fibrosis mutant G551D-CFTR.
    Xu Z; Pissarra LS; Farinha CM; Liu J; Cai Z; Thibodeau PH; Amaral MD; Sheppard DN
    J Physiol; 2014 May; 592(9):1931-47. PubMed ID: 24591578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.